Ian Read, Pfizer Chairman and Chief Executive Officer, stated, “Overall, 2011 was a year of setting new direction and focus for Pfizer. I am pleased with our 2011 financial performance, which was achieved in the face of a challenging global market and product losses of exclusivity of approximately $5 billion. We also made significant progress regarding capital allocation for the benefit of our shareholders during 2011.” “In 2011, we advanced our pipeline and improved the rigor and productivity of our research and development (R&D) efforts, while also changing the culture within the R&D organization to be more accountable and results-driven. With the steady cadence of new product launches, marketing submissions and approvals, and positive late-stage clinical data presentations, we are clearly seeing the benefits of our investments and new approach. Prevnar/Prevenar 13 for adults, tofacitinib, Xalkori, Inlyta (axitinib) and Eliquis are well positioned to be important new product opportunities that may enhance the performance of our business. Additionally, we have a next wave of compounds that have shown promise in early and mid-stage studies, and we look forward to progressing them through the pipeline. Each of these compounds represents a potential valuable, new treatment option for patients.”

Amgen is world’s largest independent biotechnology medicines company. Amgen is in the business of discovering, developing, manufacturing and marketing medicines for grievous illnesses. Amgen focuses solely on human therapeutics and concentrate on innovating novel medicines based on advances in cellular and molecular biology. Amgen's mission is to serve patients. They were incorporated in 1980 and organized as a Delaware corporation in 1987. Amgen's public website is www.amgen.com.

As of December 31, 2010, we had 17,400 staff members worldwide. Approximately 6,700 of Amgen's staff members work in their research and development (“R&D”) function, approximately 4,600 work in manufacturing, approximately 4,200 work in it's commercial operations and the rest are in general and administrative functions.